Contrasting Citius Oncology (NASDAQ:CTOR) and Incyte (NASDAQ:INCY)

Citius Oncology (NASDAQ:CTOR) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Institutional & Insider Ownership

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 7.8% of Citius Oncology shares are held by insiders. Comparatively, 17.8% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Citius Oncology and Incyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-55.19%	-23.99%
Incyte	25.03%	26.34%	18.71%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Citius Oncology and Incyte, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	2	0	2.33
Incyte	1	11	9	0	2.38

Citius Oncology presently has a consensus price target of $6.00, indicating a potential upside of 1,072.33%. Incyte has a consensus price target of $104.89, indicating a potential upside of 16.16%. Given Citius Oncology’s higher possible upside, analysts clearly believe Citius Oncology is more favorable than Incyte.

Volatility & Risk

Citius Oncology has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Valuation & Earnings

This table compares Citius Oncology and Incyte”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76 million	($0.31)	-1.65
Incyte	$5.14 billion	3.50	$1.29 billion	$6.41	14.09

Incyte has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Summary

Incyte beats Citius Oncology on 11 of the 13 factors compared between the two stocks.

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.